Check out our recap of last year's advancements made in the vaccine, biosimilar, and therapeutic spaces.
2023 was a year packed with advancements in the vaccine, biosimilar, and therapeutic spaces. Explore the approvals that emerged in 2023 from these advancements in our slideshow series outlining the impact of each on the general health care landscape.
Vaccine approvals included 2 immunizations for RSV and a new pentavalent meningococcal shot.
In addition to the numerous adalimumab (Humira) biosimilars that launched this year, multiple new biosimilar products were approved by the FDA in 2023.
Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.
Last year witnessed an abundance of novel drug and therapeutic approvals, including treatments for Alzheimer’s disease, type 2 diabetes, and more.
Part 2 of this slideshow series highlights more treatments approved by the FDA in 2023, like those for amyotrophic lateral sclerosis, vasomotor symptoms of menopause, and more.
Drug approval highlights from 2023 continue, including treatments for large B-cell lymphoma, respiratory syncytial virus, and more.
Take a look back on more novel drug and therapeutic approvals, like treatments for postpartum depression, relapsed or refractory multiple myeloma, and more.
The concluding portion of this slideshow series looks at FDA approvals of treatments for ulcerative colitis, neutropenia, and more, from 2023.